Author: aweinsoff@channelchek.com

Release – ACCO Brands Corporation Declares Quarterly Dividend

Posted on by aweinsoff@channelchek.com

Research News and Market Data on ACCO

07/25/2025

    LAKE ZURICH, Ill.–(BUSINESS WIRE)– ACCO Brands Corporation (NYSE: ACCO) today announced that its board of directors has declared a quarterly cash dividend of $0.075 per share. The dividend will be paid on September 10, 2025, to stockholders of record as of the close of business on August 22, 2025.

    About ACCO Brands Corporation
    ACCO Brands is the leader in branded consumer products that enable productivity, confidence and enjoyment while working, when learning and while playing. Our widely recognized brands include AT-A-GLANCE®, Five Star®, Kensington®, Leitz®, Mead®, PowerA®, Swingline®, Tilibra® and many others. More information about ACCO Brands Corporation (NYSE: ACCO) can be found at www.accobrands.com.

    Chris McGinnis
    Investor Relations
    (847) 796-4320

    Kori Reed
    Media Relations
    (224) 501-0406

    Source: ACCO Brands Corporation

    Release – CVG Announces Second Quarter 2025 Earnings Call

    Posted on by aweinsoff@channelchek.com

    Research News and Market Data on CVGI

    July 24, 2025

    NEW ALBANY, Ohio, July 24, 2025 (GLOBE NEWSWIRE) — Commercial Vehicle Group (the “Company” or “CVG”) (NASDAQ: CVGI) will hold its quarterly conference call on Tuesday, August 5, 2025, at 8:30 a.m. ET, to discuss second quarter 2025 financial results. CVG will issue a press release and presentation prior to the conference call.

    Toll-free participants dial (800) 549-8228 using conference code 72110. International participants dial (289) 819-1520 using conference code 72110. This call is being webcast and can be accessed through the “Investors” section of CVG’s website at ir.cvgrp.com where it will be archived for one year.

    A telephonic replay of the conference call will be available until August 19, 2025. To access the replay, toll-free callers can dial (+1) 888 660 6264 using access code 72110 #, and toll callers in North America and other locations can dial (+1) 289 819 1325.

    About CVG

    At CVG, we deliver real solutions to complex design, engineering and manufacturing problems while creating positive change for our customers, industries, and communities we serve. Information about the Company and its products is available on the internet at www.cvgrp.com.

    Investor Relations Contact:
    Ross Collins or Stephen Poe
    Alpha IR Group
    CVGI@alpha-ir.com

    Primary Logo

    Source: Commercial Vehicle Group, Inc.

    Release – NN, Inc. to Hold Second Quarter 2025 Earnings Conference Call on Thursday, August 7, 2025

    Posted on by aweinsoff@channelchek.com

    Research News and Market Data on NNBR

    PDF Version

    CHARLOTTE, N.C., July 24, 2025 (GLOBE NEWSWIRE) — NN, Inc. (NASDAQ: NNBR), a global diversified industrial company that engineers and manufactures high-precision components and assemblies, announced today that it will release its second quarter 2025 financial results for the period ended June 30th, 2025, after the close of the market on Wednesday, August 6th, 2025. The Company will hold a related conference call on Thursday, August 7th, 2025, at 9:00 a.m. E.T. Participants on the call are asked to register five to ten minutes prior to the scheduled start time by dialing 1-888-999-3182 and from outside the U.S. at 1-848-280-6330.

    The conference call will be webcast simultaneously and in its entirety through the NN, Inc. Investor Relations website. Shareholders, media representatives and others may participate in the webcast by registering through the Investor Relations section on the company’s website at https://investors.nninc.com/.

    For those who are unavailable to listen to the live call, a replay will be available shortly after the call on NN’s website through August 8th, 2026.

    About NN, Inc.
    NN, Inc., a global diversified industrial company, combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision components and assemblies for a variety of markets on a global basis. Headquartered in Charlotte, North Carolina, NN has facilities in North America, Europe, South America, and Asia. For more information about the company and its products, please visit www.nninc.com.

    Investor Relations:
    Joe Caminiti or Stephen Poe
    NNBR@alpha-ir.com
    312-445-2870

    Primary Logo

    Source: NN, Inc.

    Release – The Oncology Institute Announces Second Quarter 2025 Earnings Release Date and Conference Call

    Posted on by aweinsoff@channelchek.com

    Research News and Market Data on TOI

    Jul 24, 2025

    PDF Version

    CERRITOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) — The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that the company will release its second quarter 2025 financial results after the market close on Wednesday, August 13, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).

    The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13754165. The replay will be available until Wednesday, August 20, 2025.

    Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company’s website at https://investors.theoncologyinstitute.com/.

    About The Oncology Institute

    Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of over 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. With over 120 employed clinicians and more than 700 teammates in over 70 clinic locations, TOI is changing oncology for the better. For more information, visit www.theoncologyinstitute.com

    Contacts

    Media

    The Oncology Institute, Inc.
    marketing@theoncologyinstitute.com

    Investors

    ICR Healthcare
    TOI@icrhealthcare.com

    Release – GeoVax to Advance Gedeptin(R) into First-Line Therapy Neoadjuvant Combination Trial Following Landmark KEYNOTE-689 Results

    Posted on by aweinsoff@channelchek.com

    Research News and Market Data on GOVX

      Revised Phase 2 Strategy Targets Event-Free Survival in Primary Head and Neck Cancer through Checkpoint Inhibitor Combination

      ATLANTA, GA, July 24, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced a strategic shift in its Gedeptin® clinical development program, with a new emphasis on evaluating Gedeptin as a neoadjuvant therapy in combination with pembrolizumab for patients with primary, resectable head and neck squamous cell carcinoma (HNSCC).

      The revised strategy follows the landmark results of the KEYNOTE-689 Phase 3 trial, published in the New England Journal of Medicine on June 18, 2025, which demonstrated a significant improvement in event-free survival (EFS) with the addition of perioperative pembrolizumab in resectable, locally advanced HNSCC patients. These data represent the first validated use of PD-1 inhibition in curative-intent HNSCC and have catalyzed a major shift in treatment paradigms toward neoadjuvant immunotherapy.

      GeoVax’s new Phase 2 trial (AdPNP-203) will evaluate the addition of intra-tumoral Gedeptin®, intravenous fludarabine, and pembrolizumab in patients eligible for curative surgery. The trial is designed to assess major pathological response (MPR) and associated immunologic and biomarker outcomes following two pre-surgical cycles of therapy as well as event-free survival over a one-year period. Gedeptin’s tumor-targeting, immune-sensitizing mechanism may help overcome the limitations of checkpoint monotherapy by enhancing immune activation within the tumor microenvironment. Trial initiation is planned for 2026.

      “The KEYNOTE-689 results support our view that neoadjuvant checkpoint inhibition can transform the treatment of head and neck cancer,” said Dr. Kelly McKee, Chief Medical Officer at GeoVax. “By integrating Gedeptin into this emerging standard, we hope to improve both local tumor clearance and event-free survival, especially for high-risk or PD-L1-low patients.”

      “This is a strategic shift in our program,” added David Dodd, Chairman and CEO of GeoVax. “We believe Gedeptin’s localized cytotoxic mechanism, when combined with systemic checkpoint inhibition for first-line treatment, can meaningfully improve therapeutic outcomes in patients with resectable HNSCC.”

      Rationale for Combination Strategy

      As highlighted in the NEJM editorial, the benefit in KEYNOTE-689 may be driven primarily by the neoadjuvant component of immunotherapy. However, many patients still experience local or distant relapse, underscoring the need for intensified strategies in the perioperative window. Gedeptin, with its dual cytotoxic and immune-priming mechanism, may serve as an ideal partner to checkpoint inhibitors by converting “cold” tumors into “hot” immunogenic targets.

      About Gedeptin®

      Gedeptin is a gene-directed enzyme prodrug therapy (GDEPT) using a non-replicating adenoviral vector encoding purine nucleoside phosphorylase (PNP). Once delivered directly into tumors and followed by fludarabine, PNP enzymatically converts the prodrug into a cytotoxic compound, selectively targeting tumor cells while sparing healthy tissue. This localized approach aims to reduce toxicity, enhance immune visibility, and enable immune checkpoint synergy.

      Gedeptin has received Orphan Drug Designation for oral and pharyngeal cancers and is backed by a robust intellectual property portfolio. GeoVax’s ongoing innovation in immune-sensitizing therapies supports a broader strategy to complement checkpoint inhibitors and overcome tumor immune resistance across solid tumor types.

      About GeoVax

      GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

      Forward-Looking Statements

      This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

      Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

      Company Contact:

      info@geovax.com

      678-384-7220

      Investor Relations Contact:

      geovax@precisionaq.com

      212-698-8696

      Media Contact:

      Jessica Starman

      media@geovax.com

      Release – Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology

      Posted on by aweinsoff@channelchek.com

      Research News and Market Data on UNCY

      July 24, 2025 8:00am EDT Download as PDF

      OLC was well-tolerated and enabled serum phosphate control in over 90% of patients with a low pill burden

      LOS ALTOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced the publication of pivotal trial data describing the safety and tolerability of oxylanthanum carbonate (OLC) in chronic kidney disease (CKD) patients on dialysis in the Clinical Journal of the American Society of Nephrology.

      The publication, entitled “A Phase 2 Clinical Trial of Oxylanthanum Carbonate in Patients Receiving Maintenance Hemodialysis with Hyperphosphatemia,” examines the safety and tolerability of OLC at clinically effective doses with a goal serum phosphate concentration of ≤5.5 mg/dL. Eighty-six patients were treated with OLC in this open-label single arm Phase 2 study. At screening, only 59% of patients had serum phosphate levels of ≤5.5 mg/dL (phosphate control). OLC was well tolerated and enabled serum phosphate control in >90% of patients with a low pill burden (two-thirds of patients receiving three or fewer tablets/day). Pharmacokinetic analysis showed that systemic absorption of OLC (measured as lanthanum) was minimal to none in CKD patients.

      “With the favorable tolerability, strong efficacy and low pill burden highlighted in this prestigious publication, we continue to believe that OLC has the potential to offer patients a new option that could help improve adherence to treatment over time,” said Shalabh Gupta, MD, Chief Executive Officer of Unicycive. “This pivotal study was the final clinical evidence needed for our NDA package. We continue to collaborate closely with the U.S. Food and Drug Administration as we address their outstanding manufacturing questions and align on a path forward to bring OLC to this underserved patient population as quickly as possible.”

      Key Findings:

      • More than 90% of patients with hyperphosphatemia taking OLC achieved effective phosphate control.
      • Two-thirds of patients required three or fewer OLC tablets per day to achieve target serum phosphate levels, with most requiring no more than one tablet with each meal.
      • OLC was well tolerated in CKD patients on dialysis. The most common treatment-related adverse events were gastrointestinal (9% diarrhea; 6% vomiting) and only 4% of patients discontinued treatment due to treatment-related adverse events.

      “Despite the various treatment options available, there remains a significant need in managing hyperphosphatemia, which heavily impacts people with chronic kidney disease on dialysis,” said Dr. Pablo Pergola, MD, PhD, Research Director, Clinical Advancement Center, Renal Associates, P.A., and principal investigator of the trial. “These data add to the growing body of clinical evidence supporting the potential of OLC as an innovative treatment option, demonstrating effective phosphate control and reducing pill burden. OLC’s unique profile offers a promising alternative with favorable tolerability, potentially transforming the standard of care for patients.”

      The full publication can be accessed here and on the Presentations & Research page of Unicycive’s website.

      About Oxylanthanum Carbonate (OLC)
      OLC is an investigational oral phosphate binder that leverages proprietary nanoparticle technology to deliver high phosphate binding potency, reducing the number and size of pills that patients must take to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden.

      Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. The NDA submission package is based on data from three clinical studies (a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers, and a tolerability study of OLC in CKD patients on dialysis), multiple preclinical studies, and the chemistry, manufacturing and controls (CMC) data. OLC is protected by a strong global patent portfolio including issued patents on composition of matter with exclusivity until 2031, and with the potential for patent term extension until 2035.

      About Hyperphosphatemia
      Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). Annually there are over 450,000 individuals in the U.S. that require medication to control their phosphate levels.1 Uncontrolled hyperphosphatemia is strongly associated with increased death and hospitalization for CKD patients on dialysis. Treatment of hyperphosphatemia is aimed at lowering serum phosphate levels via two means: (1) restricting dietary phosphorus intake; and (2) using, on a daily basis, and with each meal, oral phosphate binding drugs that facilitate fecal elimination of dietary phosphate rather than its absorption from the gastrointestinal tract into the bloodstream.

      1Flythe JE. Dialysis-Past, Present, and Future: A Kidney360 Perspectives Series. Kidney360. 2023 May 1;4(5):567-568. doi: 10.34067/KID.0000000000000145. Epub 2023 Jun 29. PMID: 37229723; PMCID: PMC10371371.

      About Unicycive Therapeutics
      Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted Orphan Drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.

      Forward-looking statements
      Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

      Investor Contacts:

      Kevin Gardner
      LifeSci Advisors
      kgardner@lifesciadvisors.com

      Media Contact:

      Rachel Visi
      Real Chemistry
      redery@realchemistry.com

      SOURCE: Unicycive Therapeutics, Inc.

      Primary Logo

      Source: Unicycive Therapeutics, Inc.

      Released July 24, 2025

      Release – Kelly Announces Second-Quarter 2025 Conference Call

      Posted on by aweinsoff@channelchek.com

      Research News and Market Data on KELYA

      July 24, 2025

      PDF Version

      TROY, Mich., July 24, 2025 (GLOBE NEWSWIRE) — Kelly, a leading global specialty talent solutions provider, will release its second-quarter earnings before the market opens on Thursday, August 7, 2025. In conjunction with its earnings release, Kelly will publish a financial presentation and host a live webcast of a conference call with financial analysts at 9 a.m. ET on August 7 to review the results from the quarter and answer questions.

      The presentation and a link to the live webcast will be accessible through the Company’s public website on the Investor Relations page under Events & Presentations. The webcast will be recorded, and a replay will be available within one hour of completion of the event through the same link as the live webcast.

      About Kelly

      Kelly Services, Inc. (Nasdaq: KELYA, KELYB) helps companies recruit and manage skilled workers and helps job seekers find great work. Since inventing the staffing industry in 1946, we have become experts in the many industries and local and global markets we serve. With a network of suppliers and partners around the world, we connect more than 400,000 people with work every year. Our suite of outsourcing and consulting services ensures companies have the people they need, when and where they are needed most. Headquartered in Troy, Michigan, we empower businesses and individuals to access limitless opportunities in industries such as science, engineering, technology, education, manufacturing, retail, finance, and energy. Revenue in 2024 was $4.3 billion. Learn more at kellyservices.com.

      KLYA-FIN

      Analyst & Media Contact:
      Scott Thomas
      (248) 251-7264
      scott.thomas@kellyservices.com

      Release – The ODP Corporation to Announce Second Quarter 2025 Results Wednesday, August 6th, 2025

      Posted on by aweinsoff@channelchek.com

      Research News and Market Data on ODP

      PDF Version

      BOCA RATON, Fla.–(BUSINESS WIRE)–Jul. 23, 2025– The ODP Corporation (NASDAQ:ODP) (“ODP,” or the “Company”), a leading provider of products, services, and technology solutions to businesses and consumers, will announce second quarter 2025 financial results before the market open on Wednesday, August 6th, 2025. The ODP Corporation will webcast a call with financial analysts and investors that day at 9:00 am Eastern Time which will be accessible to the media and the general public.

      To listen to the conference call via webcast, please visit The ODP Corporation’s Investor Relations website at investor.theodpcorp.com. A replay of the webcast will be available approximately two hours following the event. A copy of the earnings press release, supplemental financial disclosures and presentation will also be available on the website.

      About The ODP Corporation
      The ODP Corporation (NASDAQ:ODP) is a leading provider of products and services through an integrated business-to-business (B2B) distribution platform and omni-channel presence, which includes supply chain and distribution operations, dedicated sales professionals, online presence, and a network of Office Depot and OfficeMax retail stores. Through its operating companies ODP Business Solutions, LLC; Office Depot, LLC; and Veyer, LLC, The ODP Corporation empowers every business, professional, and consumer to achieve more every day. For more information, visit theodpcorp.com.

      ODP and ODP Business Solutions are trademarks of ODP Business Solutions, LLC. Office Depot is a trademark of The Office Club, LLC. OfficeMax is a trademark of OMX, Inc. Veyer is a trademark of Veyer, LLC. Grand&Toy is a trademark of Grand & Toy, LLC in Canada. Any other product or company names mentioned herein are the trademarks of their respective owners.

      Tim Perrott
      Investor Relations
      561-438-4629
      Tim.Perrott@theodpcorp.com

      Source: The ODP Corporation

      Release – Conduent to Report Second-Quarter 2025 Financial Results on August 6, 2025

      Posted on by aweinsoff@channelchek.com

      Research News and Market Data on CNDT

        July 23, 2025

        Earnings/Financial

        FLORHAM PARK, N.J. — Conduent Incorporated (Nasdaq: CNDT), a global technology-driven business solutions and services company, plans to report its second-quarter 2025 financial results on Wednesday, Aug. 6, 2025 before market open. Management will present the results during a conference call and webcast at 9:00 a.m. ET.

        The call will be available by live audiocast along with the news release and online presentation slides at https://investor.conduent.com.

        The conference call will also be available by calling 877-407-4019 toll free. If requested, the conference ID is 13754400.

        The international dial-in is +1 201-689-8337. The international conference ID is also 13754400.

        A recording of the conference call will be available by calling 877-660-6853 three hours after the conference call concludes. The access ID for the recording is 13754400.

        The call recording will be available until Aug. 20, 2025.

        We look forward to your participation.

        About Conduent
        Conduent delivers digital business solutions and services spanning the commercial, government and transportation spectrum – creating valuable outcomes for its clients and the millions of people who count on them. The Company leverages cloud computing, artificial intelligence, machine learning, automation and advanced analytics to deliver mission-critical solutions. Through a dedicated global team of approximately 56,000 associates, process expertise and advanced technologies, Conduent’s solutions and services digitally transform its clients’ operations to enhance customer experiences, improve performance, increase efficiencies and reduce costs. Conduent adds momentum to its clients’ missions in many ways including disbursing approximately $85 billion in government payments annually, enabling 2.3 billion customer service interactions annually, empowering millions of employees through HR services every year and processing nearly 13 million tolling transactions every day. Learn more at www.conduent.com.

        Note: To receive RSS news feeds, visit www.news.conduent.com. For open commentary, industry perspectives and views, visit http://twitter.com/Conduent, http://www.linkedin.com/company/conduent or http://www.facebook.com/Conduent.

        Trademarks
        Conduent is a trademark of Conduent Incorporated in the United States and/or other countries. Other names may be trademarks of their respective owners.

        Media Contacts

        Sean Collins

        Conduent

        Sean.Collins2@conduent.com

        +1-310-497-9205

        David Chen

        Conduent

        ir@conduent.com

        Release – Travelzoo Reports Second Quarter 2025 Results

        Posted on by aweinsoff@channelchek.com
        Travelzoo logo

        Research News and Market Data on TZOO

        Jul 23, 2025, 07:30 ET

        NEW YORK, July 23, 2025 /PRNewswire/ — Travelzoo® (NASDAQ: TZOO):

        • Revenue of $23.9 million, up 13% year-over-year
        • Consolidated operating profit of $2.1 million
        • Non-GAAP consolidated operating profit of $2.4 million
        • Cash flow from operations of $1.3 million
        • Earnings per share (EPS) of $0.12

        Travelzoo, the club for travel enthusiasts, today announced financial results for the second quarter ended June 30, 2025. Consolidated revenue was $23.9 million, up 13% from $21.1 million year-over-year. In constant currencies, revenue was $23.5 million, up 12% year-over-year. Travelzoo’s reported revenue consists of advertising and commerce revenues, derived from and generated in connection with purchases made by Travelzoo members, and membership fees.

        In Q2, Travelzoo invested significantly in acquiring more Club Members when we saw that we can achieve a payback and positive return on investment (ROI) within the quarter. Marketing costs were expensed immediately. Membership fees revenue is recognized ratably over the subscription period of 12 months. The effect is a sizable reduction in EPS. We refer to our investor presentation.

        Net income attributable to Travelzoo was $1.4 million for Q2 2025, or $0.12 per share, compared with $0.23 per share in the prior-year period.

        Non-GAAP operating profit was $2.4 million. Non-GAAP operating profit excludes amortization of intangibles ($16,000), stock option expenses ($339,000), and severance-related expenses ($6,000). Please refer to “Non-GAAP Financial Measures” and the tabular reconciliation below.

        “We will continue to leverage Travelzoo’s global reach, trusted brand, and strong relationships with top travel suppliers to negotiate more Club Offers for Club Members and add new benefits, such as our popular complementary airport lounge access worldwide in case of a delayed flight,” said Holger Bartel, Travelzoo’s Global CEO. “Travelzoo members are affluent, active, and open to new experiences. We inspire travel enthusiasts to travel to places they never imagined they could. Travelzoo is the must-have membership for those who love to travel as much as we do.”

        Travelzoo North America

        North America business segment revenue increased 14% year-over-year to $16.1 million. Operating profit for Q2 2025 was $2.8 million, or 17% of revenue, compared to operating profit of $3.7 million or 26% of revenue in the prior-year period.

        Travelzoo Europe

        Europe business segment revenue increased 7% year-over-year to $6.4 million. Operating loss for Q2 2025 was $883,000, or 14% of revenue, compared to operating profit of $512,000, or 9% of revenue in the prior-year period. The reported operating loss occurred because we acquired more Club Members.

        Jack’s Flight Club

        Jack’s Flight Club is a membership subscription service in which Travelzoo has a 60% ownership interest. Revenue increased 33% year-over-year to $1.4 million. The number of premium subscribers increased 15% year-over-year. Jack’s Flight Club’s revenue from subscriptions is recognized ratably over the subscription period (quarterly, semi-annually, annually). Operating profit for Q2 2025 was $156,000, compared to an operating loss of $34,000 in the prior-year period.

        New Initiatives

        New Initiatives business segment revenue, which includes Licensing and Travelzoo META, was $19,000. Operating loss for Q2 2025 was $31,000.

        In 2020, Travelzoo entered into royalty-bearing licensing agreements with local licensees for the exclusive use of Travelzoo’s brand, business model, and members in  Australia, Japan, New Zealand, and Singapore. Under these arrangements, Travelzoo’s existing members in Australia, Japan, New Zealand, and Singapore will continue to be owned by us as the licensor. Licensing revenue from the licensee in Australia was $10,000 for Q2 2025. Licensing revenue from the licensee in Japan was $7,000 for in Q2 2025. Licensing revenue is expected to increase going forward.

        Reach

        Travelzoo reaches 30 million travelers. This includes Jack’s Flight Club. Comparisons to prior periods are no longer meaningful due to strategic developments of the Travelzoo membership.

        Income Taxes

        The reported income tax provision and reserves for Q2 2025 are $740,000. Travelzoo intends to utilize available net operating losses (NOLs) to largely offset its tax liability for Q2 2025.

        Balance Sheet

        Deferred revenue increased and is expected to continue to increase as membership fees revenue is recognized ratably over the subscription period.

        As of June 30, 2025, cash, cash equivalents and restricted cash were $11.2 million. Cash flow from operations was $1.3 million.

        Share Repurchase Program

        During Q2 2025, the Company repurchased 172,088 shares of its outstanding common stock.

        Looking Ahead

        For Q3 2025, we expect year-over-year revenue growth to continue. We expect revenue growth to accelerate as a trend in subsequent quarters, as membership fees revenue is recognized ratably over the subscription period of 12 months, as we acquire new members, and as more Legacy Members become Club Members. Over time, we expect profitability to substantially increase as recurring membership fees revenue will be recognized. In the short-term, fluctuations in reported net income are possible. We might see attractive opportunities to increase marketing. We expense marketing costs immediately.

        In 2024, we introduced a membership fee for Travelzoo. Legacy Members, who joined prior to 2024, continue to receive certain travel offers. However, Club Offers and new benefits are only available to Club Members, who pay the membership fee. Therefore, we are seeing many Legacy Members become Club Members over time—in addition to new members who join.

        Non-GAAP Financial Measures

        Management calculates non-GAAP operating income when evaluating the financial performance of the business. Calculation of non-GAAP operating income, also called “non-GAAP operating profit” in this press release and today’s earnings conference call, excludes the following items: amortization of intangibles, stock option expenses, and severance-related expenses. This press release includes a table which reconciles GAAP operating income to the calculation of non-GAAP operating income. Non-GAAP operating income is not required by, or presented in accordance with, generally accepted accounting principles in the United States of America (“GAAP”). This information should be considered as supplemental in nature and should not be considered in isolation or as a substitute for the financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similarly titled measures reported by other companies.

        Conference Call

        Travelzoo will host a conference call to discuss second quarter 2025 results today at 11:00 a.m. ET. Please visit http://ir.travelzoo.com/events-presentations to

        • download the management presentation (PDF format) to be discussed in the conference call
        • access the webcast.

        About Travelzoo

        We, Travelzoo®, are the club for travel enthusiasts. We reach 30 million travelers. Club Members receive Club Offers personally reviewed by our deal experts around the globe. We have our finger on the pulse of outstanding travel, entertainment, and lifestyle experiences. We work in partnership with thousands of top travel suppliers—our long-standing relationships give us access to irresistible deals.

        Certain statements contained in this press release that are not historical facts may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. These forward-looking statements may include, but are not limited to, statements about our plans, objectives, expectations, prospects and intentions, markets in which we participate and other statements contained in this press release that are not historical facts. When used in this press release, the words “expect”, “predict”, “project”, “anticipate”, “believe”, “estimate”, “intend”, “plan”, “seek” and similar expressions are generally intended to identify forward-looking statements. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including changes in our plans, objectives, expectations, prospects and intentions and other factors discussed in our filings with the SEC. We cannot guarantee any future levels of activity, performance or achievements. Travelzoo undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

        Investor Relations:
        ir@travelzoo.com 

        View full release here.

        Release – NN, Inc. Appoints Tim Erro as New Chief Commercial Officer, Expands New Business Program

        Posted on by aweinsoff@channelchek.com

        Research News and Market Data on NNBR

        PDF Version

        CHARLOTTE, N.C., July 22, 2025 (GLOBE NEWSWIRE) — NN, Inc. (NASDAQ: NNBR), a global diversified industrial company that engineers and manufactures high-precision components and assemblies, today announced Timothy Erro has joined as its new Vice President and Chief Commercial Officer.  In this position, Mr. Erro will lead NN’s global commercial team and report directly to Harold Bevis, President and CEO.

        NN has a successful new business program and as a function of this early success, the Company is announcing a commitment to expand this program with this announced leadership change. NN has shown strong initial results in the last two years.

        • Approximately $160 million of new business wins since launching the initiative in 2023, with success primarily in the Company’s traditional markets and emerging success in electrical and medical end markets.
        • NN’s new business pipeline remains robust at more than $700 million across all products and targeted growth areas.

        NN is revising and increasing its overall new business objectives:

        • Increasing its targets and the pace for achieving new wins, specifically in electrical and medical markets;
        • Setting higher annual award goals; and
        • Strategically expanding product offerings and solutions.

        Tim Erro has led a highly successful global team and program, and has overseen a significant amount of business growth and new wins, including:

        • Leading a global team effort that has averaged more than $50 million per year in new business wins of electrical products, more than three times the historical annual new business wins generated by NN’s Power Solutions division; and
        • Entering eight new markets, through which his teams have added many new customers in pursuit of electrical products and systems that fit his prior company’s operating assets and know-how.

        Harold Bevis, President and Chief Executive Officer of NN commented, “Tim brings an outstanding track record with him and is currently leading one of the most successful new wins programs in the electrical industry globally. He is an expert at entering new markets and expanding market share in existing markets. He has a great blend of technical and commercial expertise, operations know-how, and executive leadership experience, all of which align with our commercial strategy and will help take NN’s growth program to the next level. He and I have worked together in the past, where he led a tremendously successful global program focused on electrical and electronic products at a much larger scale than our current program. His track record of developing and leading high-performing sales organizations will help us achieve our goals faster.”

        Erro has more than 30 years of experience with electrical and electronic products across a wide variety of end markets and global geographies, including:

        • On-road commercial vehicles;
        • Vocational vehicles – buses, transit, refuse;
        • Aerospace and defense platforms;
        • Automotive passenger vehicles and trucks;
        • Last mile delivery vehicles;
        • Recreational vehicles – golf carts, ATVs, motorcycles;
        • Off-road construction and agricultural equipment;
        • Gas, diesel and hydrogen engines;
        • Chassis and battery platforms;
        • High and low voltage systems;
        • Wide variety of connector systems; and
        • Windshield wiper systems.

        Mr. Bevis concluded, “From our past experience together, I can attest that Tim will increase our focus, pace, hit rates, and the accountability of our global commercial team along our chosen paths. He will strengthen our team and immediately bring in new talent. As part of our enhanced commercial efforts, we especially want to grow at a more accelerated pace in electrical products and medical products.”

        Tim Erro commented, “I am excited to join NN’s leadership team and am eager to put my background and industry experience to work in strengthening NN’s commercial results and our global team. Our engineering and production capabilities are unique and highly valued in the market, and I look forward to working with the talented team at NN to set even higher goals and achieve them with consistency. This is going to be an exciting next phase for NN, and I plan to bring in additional experienced veterans to lead the way with our customers.”

        Mr. Erro brings an extensive commercial and operations background with him. Prior to joining NN, he served as VP of Global Sales and New Business Development for Commercial Vehicle Group, Inc., and has had a focused set of sales and operations roles at Aptiv (formerly Delphi Automotive), Leoni Wiring Systems, General Motors, and United Technologies Automotive. A highlight of his engineering tenure includes leading the design and execution of fully functional concept vehicles for major global auto shows, showcasing advanced technology trends and innovations. Mr. Erro also proudly served 12 years in the US Navy reserves. He holds a Bachelor of Science in Mechanical Engineering from Youngstown State University.  

        About NN, Inc.

        NN, Inc., a global diversified industrial company, combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision components and assemblies for a variety of markets on a global basis. Headquartered in Charlotte, North Carolina, NN has facilities in North America, Europe, South America, and Asia. For more information about the company and its products, please visit www.nninc.com. 

        Investor Relations: 
        Joe Caminiti or Stephen Poe, Investors 
        NNBR@alpha-ir.com  
        312-445-2870 

        Primary Logo

        Source: NN, Inc.

        Release – GeoVax to Report Second Quarter 2025 Financial Results and Provide Corporate Update on July 28, 2025

        Posted on by aweinsoff@channelchek.com

        Research News and Market Data on GOVX

          GeoVax to Host Conference Call at 4:30 PM ET

          Atlanta, GA, July 22, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today announced that it will report second quarter 2025 financial results on Monday, July 28, 2025, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results.

          Conference Call Details

          To access the live conference call, participants may register here. The live audio webcast of the call will be available under “Events and Presentations” in the Investor Relations section of the GeoVax website at geovax.com/investors. To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. An archive of the audio webcast will be available on GeoVax’s website approximately two hours after the conference call and will remain available for at least 90 days following the event.

          About GeoVax

          GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

          Company Contact:

          info@geovax.com

          678-384-7220

          Investor Relations Contact:

          geovax@precisionaq.com

          212-698-8696

          Media Contact:

          Jessica Starman

          media@geovax.com 

          Release – Conduent Expands Deployment of EBT Solutions to Prevent Fraud and Improve Customer Experiences Across U.S. States

          Posted on by aweinsoff@channelchek.com

          Research News and Market Data on CNDT

          July 22, 2025 at 8:45 AM EDT

          PDF Version

          Lock/Unlock Feature Now Live in 12 States to Help Safeguard SNAP Benefits

          FLORHAM PARK, N.J.–(BUSINESS WIRE)–Jul. 22, 2025– Conduent Incorporated (Nasdaq: CNDT), a global technology-driven business solutions and services company, announced the continued deployment of its Electronic Benefits Transfer (EBT) solutions to enhance security and the end-user experience. These enhancements include fraud prevention tools such as intelligent voice systems that detect suspicious calls, technologies enabling the planned move to EBT chip cards and mobile wallet integration, as well as a Conduent feature that locks and unlocks accounts, which is now being used in 12 U.S. states.

          The lock/unlock feature enables recipients of government assistance – specifically participants in the Supplemental Nutrition Assistance Program (SNAP) – to lock and unlock their EBT accounts through Conduent’s ConnectEBT mobile app and cardholder portal.

          Benefit recipients can lock their card to block all purchases or limit the blocking to purchases outside of their home state, giving them greater control and helping to prevent unauthorized access by fraudsters.

          Technology Backed by Conduent’s VeriSight Anti-Fraud Suite

          The account control feature is part of Conduent’s VeriSight Anti-Fraud Suite, a set of innovative tools available to state agencies to address threats of fraud in public benefit programs. The 12 Conduent-supported states currently offering the lock/unlock functionality are Alabama, Delaware, Georgia, Indiana, Iowa, Maryland, New Jersey, Ohio, Oklahoma, Pennsylvania, South Carolina, and Virginia – with additional states expected to adopt the technology in the near future.

          Intelligent IVR and Real-Time Alerts

          Beyond account locking, Conduent’s VeriSight suite includes an advanced interactive voice response (IVR) system for EBT customer service centers. The system uses behavioral analytics to detect patterns such as excessive calls from a single number, enabling real-time restrictions to prevent suspicious access attempts.

          Additionally, users of Conduent’s ConnectEBT app can opt in to receive real-time usage alerts – empowering them to quickly detect and report potentially fraudulent activity.

          Future EMV Chip and Mobile Wallet Integration

          Meanwhile, Conduent continues to work with several states to prepare for the introduction of SNAP cards with EMV (Europay, Mastercard, and Visa) chip technology, which will further boost card security and reduce fraud risks at points of sale. The company is also poised to support state implementations of mobile wallet functionality, including Apple Pay and Google Pay, to bring added convenience and modernize benefit access.

          “With decades of experience in helping state agencies serve residents more effectively, operate more efficiently, and ensure that public aid goes to the intended recipients, our EBT lock-and-unlock feature is one of many solutions Conduent is delivering to combat fraud that threatens taxpayer funds,” said Anna Sever, President, Government Solutions at Conduent. “Our team continues to make progress in implementing important features in more states, while also integrating AI technologies to automate processes, improve efficiency, and reduce costs, while improving service for the people who depend on these critical benefits.”

          Conduent is a leading provider of government payment disbursements for federally funded benefit and payment card programs. The company also supports U.S. agencies with end-to-end solutions for healthcare claims processing, eligibility and enrollment, and child support administration.

          About Conduent
          Conduent delivers digital business solutions and services spanning the commercial, government and transportation spectrum – creating valuable outcomes for its clients and the millions of people who count on them. The Company leverages cloud computing, artificial intelligence, machine learning, automation and advanced analytics to deliver mission-critical solutions. Through a dedicated global team of approximately 56,000 associates, process expertise and advanced technologies, Conduent’s solutions and services digitally transform its clients’ operations to enhance customer experiences, improve performance, increase efficiencies and reduce costs. Conduent adds momentum to its clients’ missions in many ways including disbursing approximately $85 billion in government payments annually, enabling 2.3 billion customer service interactions annually, empowering millions of employees through HR services every year and processing nearly 13 million tolling transactions every day. Learn more at www.conduent.com.

          Forward-Looking Statements
          This press release, any exhibits or attachments to this release, and other public statements we make may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “estimate,” “expect,” “expectations,” “in front of us,” “plan,” “intend,” “will,” “aim,” “should,” “could,” “forecast,” “target,” “may,” “continue to,” “looking to continue,” “endeavor,” “if,” “growing,” “projected,” “potential,” “likely,” “see,” “ahead,” “further,” “going forward,” “on the horizon,” “as we progress,” “going to,” “path from here forward,” “think,” “path to deliver,” “from here,” “on track,” “remain” and similar expressions (including the negative and plural forms of such words and phrases), as they relate to us, are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. All statements other than statements of historical fact included in this press release or any attachment to this press release are forward-looking statements, including, but not limited to, statements regarding the planned adoption of technology, including all statements made under the first paragraph under the caption “Future EMV Chip and Mobile Wallet Integration” within this release. These statements reflect our current views with respect to future events and are subject to certain risks, uncertainties and assumptions, many of which are outside of our control, that could cause actual results to differ materially from those expected or implied by such forward-looking statements contained in this press release, any exhibits to this press release and other public statements we make.

          Important factors and uncertainties that could cause our actual results to differ materially from those in our forward-looking statements include, but are not limited to those factors that are set forth in the “Risk Factors” section, the “Legal Proceedings” section, the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section and other sections in our 2024 Annual Report on Form 10-K, as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with or furnished to the Securities and Exchange Commission. Any forward-looking statements made by us in this release speak only as of the date on which they are made. We are under no obligation to, and expressly disclaim any obligation to, update or alter our forward-looking statements, whether because of new information, subsequent events or otherwise, except as required by law.

          Note: To receive RSS news feeds, visit www.news.conduent.com. For open commentary, industry perspectives and views, visit http://twitter.com/Conduent, http://www.linkedin.com/company/conduent or http://www.facebook.com/Conduent.

          Trademarks
          Conduent is a trademark of Conduent Incorporated in the United States and/or other countries. Other names may be trademarks of their respective owners.

          Media Contact:
          Neil Franz, Conduent, +1-240-687-0127, neil.franz@conduent.com

          Investor Relations Contact:
          David Chen, Conduent, ir@conduent.com

          Source: Conduent Incorporated